Point72 Asia Singapore Pte. Ltd. Takes Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 21,854 shares of the company’s stock, valued at approximately $87,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VIGL. Acadian Asset Management LLC acquired a new position in shares of Vigil Neuroscience during the second quarter worth approximately $26,000. Renaissance Technologies LLC raised its stake in Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after purchasing an additional 166,442 shares during the period. Vanguard Group Inc. grew its position in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after purchasing an additional 95,276 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Vigil Neuroscience during the 2nd quarter worth about $5,940,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VIGL. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research note on Wednesday, August 14th. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research report on Thursday, July 11th. Finally, Guggenheim dropped their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Stock Up 1.2 %

Shares of NASDAQ VIGL opened at $3.44 on Friday. Vigil Neuroscience, Inc. has a 12-month low of $2.47 and a 12-month high of $9.24. The firm’s 50-day simple moving average is $3.51 and its 200 day simple moving average is $3.53. The company has a market cap of $136.40 million, a price-to-earnings ratio of -1.62 and a beta of 1.95.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. On average, equities analysts expect that Vigil Neuroscience, Inc. will post -2.15 earnings per share for the current year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.